| Robyn Alagona, MA | |
|
295 Fell St, Suite B, San Francisco, CA 94102-5147 | |
| (415) 419-2406 | |
| Not Available |
| Full Name | Robyn Alagona |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 295 Fell St, San Francisco, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003016528 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | IMF 46521 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Robyn Alagona, MA 295 Fell St, Suite B, San Francisco, CA 94102-5147 Ph: (415) 419-2406 | Robyn Alagona, MA 295 Fell St, Suite B, San Francisco, CA 94102-5147 Ph: (415) 419-2406 |
News Archive
Osteoporosis is a skeletal disease in which there is a decrease in bone mass density. The bones become more porous and fragile making them more susceptible to fracture. This disease reduces bone density and weakens the bone.
The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, said today that it will begin working with The Johnson & Johnson Corporate Office of Science and Technology, and its affiliates, to speed the development of drug targets and pathways to promote the survival and function of insulin-producing cells in people who have diabetes.
Sharps Compliance Corp., a leading full-service provider of cost-effective management solutions for medical waste and unused dispensed medications generated outside the hospital and large healthcare facility setting, today reported $5.2 million in revenue for the first quarter of fiscal year 2011 ended September 30, 2010.
InterMune, Inc. announced today that the U.S. Food and Drug Administration (FDA) has posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting to review the New Drug Application (NDA) for pirfenidone, InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. The proposed trade name for pirfenidone is Esbriet®.
› Verified 1 days ago
Ms. Darla Wolgast Romano, MFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 121 Clement St, San Francisco, CA 94118 Phone: 415-752-6775 Fax: 415-668-5309 | |
Christopher Boyd, Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 1735 Mission St, San Francisco, CA 94103 Phone: 415-762-3700 Fax: 415-746-1941 | |
Paula Victoria Cordova, MFT INTERN Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 250 Executive Park Blvd, Suite 4900, San Francisco, CA 94134 Phone: 415-656-0116 | |
Erin Hennessy, Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 1550 Treat Ave, San Francisco, CA 94110 Phone: 415-641-8000 Fax: 415-641-8002 | |
Joseph Charles Campi, MFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 4237 Geary Blvd, San Francisco, CA 94118 Phone: 415-494-9835 | |
Ashley Howard, Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 536 Leavenworth St Apt 86, San Francisco, CA 94109 Phone: 617-833-5675 |